Dec 8, 2023
January 26, 2025
This week’s newsletter included:
- BioUtah Podcast Series: “Life Sciences in Action” with James McCullough of Renalytix
- Sera Prognostics Announces Primary Endpoint Criteria Met in Pivotal PRIME Study Interim Look
- Merit Medical Announces Pricing of Upsized Private Offering of $650 Million of 3.00% Convertible Senior Notes Due 2029
- Culmination Bio Raises $10 Million from Amgen Ventures and Merck Global Health Innovation Fund
- RxCell Announces $4.6 Million Investment from DMR Global Venture and Regenosis
- Utah Life Sciences Companies Represent at MEDICA 2023
- Utah Tech Atwood Innovation Plaza: A Space to Grow Your Start-Up
- Utah Business Announces Utah’s Best Companies to Work For in 2023
- Edwards Lifesciences to Spin Off Critical Care Unit
- BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
- 100 Companies Championing Women
Featured New Member: Polsinelli
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS
